anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A human-guided rehabilitation system with dynamic feedback is provided. The human-guided rehabilitation system includes a database and a wearable device. The database includes an ideal rehabilitation trajectory parameter. The wearable device includes a plurality of static sensing modules, a plurality of dynamic sensing modules, a calibration module, an image module, and a processing module. The static sensing modules and the dynamic sensing modules can obtain a plurality of static coordinate parameters and a plurality of dynamic trajectory parameters for a rehabilitated person, respectively. The calibration module can correct the ideal rehabilitation trajectory parameter as a guide trajectory parameter according to the static coordinate parameters. The image module presents a guidance image according to the guidance trajectory parameter. When an error value between the dynamic trajectory parameters and the guide trajectory parameter that are detected by the processing module or a physiological state parameter is greater than a standard threshold, the processing module corrects the guidance trajectory parameter according to an offset of the error value compared with the guidance trajectory parameter. Accordingly, the human-guided rehabilitation system can achieve personalized and effective rehabilitation, and can save costs.
At week 0, participants will be administered aspirin 81mg (one tablet) and placebo for clopidogrel 75 mg (one tablet) once daily. At week 24, participants will stop both study product tablets.
Oxycodone is a semisynthetic pure opioid agonist whose principal therapeutic action is analgesia. Other pharmacological effects of oxycodone include anxiolysis, euphoria and feelings of relaxation. These effects are mediated by receptors (notably µ and κ) in the central nervous system for endogenous opioid-like compounds such as endorphins and enkephalins. Oxycodone produces respiratory depression through direct activity at respiratory centers in the brain stem and depresses the cough reflex by direct effect on the center of the medulla.

Acetaminophen is a non-opiate, non-salicylate analgesic and antipyretic. The site and mechanism for the analgesic effect of acetaminophen has not been determined. The antipyretic effect of acetaminophen is accomplished through the inhibition of endogenous pyrogen action on the hypothalamic heat-regulating centers.
Participants will receive 4 identical meals (equal calories and macronutrient content), over a 12-hour interval (meals at 2, 6, 10, and 14 hours after waking) centered within the 16-hour wake episode. Participants will remain in dim light (\<3 lux) throughout the 16-hour wake episode.
PROBLEM TO BE SOLVED: To obtain a fast collapsable tablet which collapses in an extremely short time, can collapse even in an oral cavity and can thereby easily be administered into an aged person or a child who has an interior swallowing ability, by granulating a sugar having a specific solubility or less, adding the powder of the sugar and then tabletting the mixture. SOLUTION: This fast collapsable tablet preferably having a collapsing time of <=5 min is obtained by granulating a sugar (for example, mannitol, lactose, erythritol) having a solubility of <=500 mg/ml, adding the powder of the sugar having a solubility of <=500 mg/ml to the obtained granules and then tabletting the mixture. The sugar powder is preferably added in an amount of 0.15 to 10 pts.wt. per 1 pt.wt. of the granules. The granulation means mixing the sugar with a binder, adding a solvent to the mixture, and simultaneously granulating the mixture by the use of a conventional kneading machine, a conventional granulating machine, a conventional fluidized layer granulating device, or the like. The addition of the powder means adding and mixing the non-granulated sugar to the granulated sugar.  The sugar to be added in the powder state is preferably used in an amount of 0.15 to 10 pts.wt. per pt.wt. of the granulated sugar.
Parkinson's disease (PD) is marked by the degeneration of dopaminergic neurons of the substantia nigra (SN), with neuroinflammation and mitochondrial dysfunction being key contributors. The neuroprotective potential of folic acid (FA) in the dopaminergic system of PD was assessed in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model. MPTP (20 mg/kg of body weight) was administered to C57BL/6J mice to simulate PD symptoms followed by FA treatment (5 mg/kg of body weight). Behavioral tests, pole, rotarod, and open-field tests, evaluated motor function, while immunohistochemistry, ELISA, RT-qPCR, and Western blotting quantified neuroinflammation, oxidative stress markers, and mitochondrial function. FA supplementation considerably improved motor performance, reduced homocysteine levels and mitigated oxidative damage in the SN. The FA-attenuated activation of the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome lessened glial cell activity and reduced neuroinflammation. At the molecular level, FA reduced DNA damage, downregulated phosphorylated p53, and induced the expression of peroxisome proliferator-activated receptor α coactivator 1α (PGC-1α), enhancing mitochondrial function. Therefore, FA exerts neuroprotection in MPTP-induced PD by inhibiting neuroinflammation via NLRP3 inflammasome suppression and promoting mitochondrial integrity through the p53-PGC-1α pathway. Notable limitations of our study include its reliance on a single animal model and the incompletely elucidated mechanisms underlying the impact of FA on mitochondrial dynamics. Future investigations will explore the clinical utility of FA and its molecular mechanisms, further advancing it as a potential therapeutic for managing and delaying the progression of PD.
* Doxorubicin hydrochloride liposome injection can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m2 to 550 mg/m2. Assess left ventricular cardiac function prior to initiation of doxorubicin hydrochloride liposome injection and during and after treatment [see Warnings and Precautions (5.1)]. 
  * Serious, life-threatening, and fatal infusion-related reactions can occur with doxorubicin hydrochloride liposome injection. Acute infusion-related reactions occurred in 11% of patients with solid tumors. Withhold doxorubicin hydrochloride liposome injection for infusion-related reactions and resume at a reduced rate. Discontinue doxorubicin hydrochloride liposome injection for serious or life-threatening infusion-related reactions [see Warnings and Precautions (5.2)].
Treatment for many head and neck cancer involves surgical resection, or removal, of the tumor. A potential outcome of surgery is subtotal resection, in which some cancerous material fails to be removed resulting in tumor recurrence and lower overall survival. Achieving total resection without interfering with normal tissue is a challenge due the critical anatomical structures of the head and neck. Fluorescent-guided surgery (FGS) is a new method of intraoperative imaging that can be used to clearly visualize cancerous tissue aprt from normal tissue during surgery in real-time. Before surgery, an agent that preferentially enters tumor cells is given to the patient. Tumor cells then glow brightly when exposed to specific wavelengths of light during surgery, allowing the surgeon to easily distinguish between healthy and cancerous tissue. 5-aminolevulinic acid (5-ALA) is a safe and effective FDA approved agent successfully used by neurosurgeons for FGS of different brain tumors which has not been assessed for use in head and neck cancers. The aim of the study is to determine if 5-ALA can be effectively used in FGS for different types of head and neck cancers, and if it will improve survival, tumor regrowth, and other outcomes for patients. 23 patients will be enrolled from the Mount Sinai Hospital, New York Eye and Ear Infirmary and Mount Sinai Union Square Faculty Practices over a 1 year period and will be completed by December 2022.
The placement of a vascular endoprosthesis (stent) is an interventional neuroradiology procedure aimed, by venous approach (percutaneous puncture), to restore the diameter of a venous sinus. It requires 6 months of antiplatelet aggregation. The aim is to allow better venous drainage from the brain to increase the absorption of cerebrospinal fluid.
The present invention relates to a method and system for diagnosing blood vessel obstruction, such as would occur in deep vein thrombosis (DVT). More specifically, the present invention relates to a software tool for use with sensor hardware to allow users to perform standardised and repeatable testing of patients to assist with diagnosis of deep vein thrombosis or related conditions. The present invention further relates to an apparatus and method for conducting the diagnosis. 
     According to a first aspect of the present invention, there is provided an apparatus for diagnosing whether a blood vessel is obstructed, comprising: an interface for communication with an imaging device which imaging device comprises a transmitter and a receiver, a user interface, and a processor, which processor is programmed to perform the following steps: inform the user, via the user interface, where to place the imaging device on a patient's body, instruct the imaging device to transmit radiation from the probe, receive reflected radiation from the imaging device, interpret the reflected information fully automatically using a learned algorithm, determine from the reflected radiation whether the imaging device is located correctly relative to a blood vessel of the patient, inform the user, if the imaging device is not located correctly, to reposition the imaging device and to repeat the instruct, receive and determine steps until the imaging device is correctly located, inform the user to apply pressure to the patient's blood vessel using the imaging device, instruct the imaging device to transmit further radiation, receive further reflected radiation from the imaging device, and determine from at least the reflected further radiation whether the blood vessel is obstructed. The system may be arranged to work with any other real-time imaging device by retraining and/or relabelling of new images. It may also work with other non-real-time methods, for example CT and MRI. For example, with a pressure cuff: scan uncompressed, scan under compression, evaluate difference. The problem may be simpler and the setup more expensive, but the same pipeline arrangement could still work. In relation to CT and MRI scans a skilled medical professional may still be required to be present doing the scan. The learned algorithm may comprise one or more elements of machine learning, and/or have been developed using machine learning.
PROBLEM TO BE SOLVED: To obtain a therapeutic agent having intestinal tract contraction inhibitory action, therefore useful in treating various diseases caused by intestinal tract motion abnormalities by including methoxyphenylethylphenoxydimethylaminopropylhydrogensuccinate hydrochloride. SOLUTION: This therapeutic agent comprises (±)-1- o-[2-(m-methoxyphenyl) ethyl]phenoxy}-3-(dimethylamino)-2-propylhydrogensuccinate hydrochloride (general name: sarpogrelate hydrochloride). This compound can be directly used as an active ingredient, however, it is preferable that the compound is formulated with pharmacologically and pharmaceutically acceptable additive(s) into a preparation. The above therapeutic agent can be administered orally or parenterally (pref. orally), and its daily dose is 0.5-50, pref. 1-30 mg/kg body weight/adult in terms of the active ingredient in the case of oral administration in the form of tablets, or the like.
Periodontal Disease Prediction (PDP) software has three components: a) Data Loading Window (DLW) b) Three-Dimensional Mouth Model (3DM) and c) Periodontal Attachment Loss Indicator (PLI). Demographic and clinical examinations of 1057 volunteers were recorded to DLW. An unsupervised machine learning K means clustering analysis was used to categorize the data obtained from the study population and identified the periodontal risk groups. An intraoral scanner was utilized to capture direct optical intraoral data of a patient and transferred to the 3DM. The intraoral model went under two algorithm steps for obtaining a recessed model. First, gingival curves separating gingiva and tooth were extracted using a Dijkstra's algorithm. Limit curves determining boundaries of recessed regions in the intraoral model were then obtained using gingival curves. The gingival recession was then mimicked by losing gingiva and disappearing tooth roots at proper locations in the intraoral model and Additionally, the final four different 3 dimensional recessed model (maxilla, mandibula, anterior teeth and posterior teeth) belonging to the same patient were scored based on the similarity to the real gingival recession by 25 periodontology specialist via online survey.
BTT1023 8mg/kg IV infusion, total of 7 infusions over 11 weeks. Duration 1-2 hours per infusion.
The invention relates to a preparation capable of treating diabetes, which is prepared from fructus corni, the rhizome of large-headed atractylodes, the larva of silkworm with botrytis, panax japonicus, ophiopogon root, fructus xanthil, alisma orientale, semen litchi, catechu lycium chinense mill, rhizoma coptidis, rhizoma ligustici wallichii, faenum graecum and the like. Rhizome anemarrhenae, sealwort, cortex lycii radicis, trichosanthes root, yam, radix puerariae, phellodendron, polygonatum, folium eriobotryae, balloon flower, gen-seng, cortex mori radicis, panax pseudo-ginseng var. notoginseng, the seed of jog's tears and the like can also be added. The preparation does not use insulin, fully exerts the multi-target pharmacological action of Chinese traditional medicines and comprehensively conditions the visceral organ at each part, thereby achieving the purpose of treating both principal and secondary aspects of diabetes. The clinical practice of the preparation in a Yu Dongshan clinique in Xiaogan City of Hubei Province indicates that the treating process is steady, various symptoms are synchronously relieved without repetition, the growth root of various complicating diseases can be eliminated, and the recurrence of diabetes can be radically avoided; the preparation also has the advantages of short treating time, remarkable and steady curative effect, no side effect, convenient administration, simple manufacture, low cost and the like. 110 cases of diabetes are treated by the preparation now.
The invention relates to heat-strengthening pills which are an internal medicine with no toxicity. With the pills, multiple heat-treating and heat-caring functions are provided. The pills are mainly used for treating heart premature beat and cardiac edema. With the pills, various heat diseases such as coronary heart disease and angina pectoris can be treated. With the pills, sudden cardiac death after sexual life can be effectively prevented. With the pills, an invigorated heart and a feeling of no chest tightness are provided for people with a pacemaker. With the pills, myocardial ischemia and hypoxia can be ameliorated, myocardial contractility can be enhanced, and arrhythmia and myocardial infarction can be prevented. With the pills, human blood flow can be enhanced, such that a person feels willing to do things and capable of doing things. A strong heart can be provided. With the pills, soldiers of special force are sturdy (a soldier is sturdy when his heart is strengthened). The heart of a person doing sport can be better. With the pills, the speaking sound of a person is louder and powerful, and the singing sound is louder and higher. With the pills, the heart of the elderly is healthier and a live preserving effect is provided. A healthy heart is the primary factor for a long life.
Most deaths in breast cancer patients are attributed to metastasis, and lung metastasis is associated with a particularly poor prognosis; therefore it is imperative to identify potential target for intervention. The transforming growth factor-β (TGF-β) pathway plays a vital role in breast cancer metastasis, in which Smad3 is the key mediator and performs specific functions by binding with different cofactors. However, Smad3 cofactors involved in lung metastasis have not yet been identified. This study first establishes the interactome of Smad3 in breast cancer cells and identifies ZNF8 as a novel Smad3 cofactor. Furthermore, the results reveal that ZNF8 is closely associated with breast cancer lung metastasis prognosis, and specifically facilitates TGF-β pathway-mediated breast cancer lung metastasis by participating in multiple processes. Mechanistically, ZNF8 binds with Smad3 to enhance the H3K4me3 modification and promote the expression of lung metastasis signature genes by recruiting SMYD3. SMYD3 inhibition by BCI121 effectively prevents ZNF8-mediated lung metastasis. Overall, the study identifies a novel cofactor of TGF-β/Smad3 that promotes lung metastasis in breast cancer and introduces potential therapeutic strategies for the early management of breast cancer lung metastasis.
Patients in the lidocaine group will receive a bolus of 1.5 mg/kg intravenous lidocaine over 10 min before induction of anesthesia. A continuous infusion of 1.5 mg/kg/hour of systemic lidocaine will be administered until the end of the surgery.
Memantine hydrochloride extended-release capsules is an orally active NMDA receptor antagonist. The chemical name for memantine hydrochloride is 1-amino-3,5-dimethyladamantane hydrochloride with the following structural formula:

The molecular formula is C12H21N•HCl and the molecular weight is 215.76. Memantine hydrochloride occurs as a fine white to off-white powder and is soluble in water.

Memantine hydrochloride extended-release capsules are supplied for oral administration as 7 mg, 14 mg, 21 mg and 28 mg capsules. Among them, 7 mg strength is supplied in opaque light green cap and opaque white body capsule, with "LPM" black imprint on the cap and "7 mg" black imprint on the body, 14 mg strength is supplied in opaque blue cap and opaque white body capsule, with "LPM" black imprint on the cap and "14 mg" black imprint on the body, 21 mg strength is supplied in opaque white cap and opaque white body capsule, with "LPM" black imprint on the cap and "21 mg" black imprint on the body, 28 mg strength is supplied in the opaque rich yellow cap and opaque white body capsule, with "LPM" black imprint on the cap and "28 mg" black imprint on the body. Each capsule contains extended-release white to off-white beads with the labeled amount of memantine hydrochloride and the following inactive ingredients: sugar spheres (sucrose, maize starch, and dextrin), polyvinylpyrrolidone, hypromellose, talc, polyethylene glycol, triethyl citrate, ethylcellulose, ammonium hydroxide, oleic acid, and medium chain triglycerides in hard gelatin capsules.

In addition, the capsule shells contain gelatin and titanium dioxide and are imprinted with black ink. Colorants in capsule shells are brilliant blue (7 mg, 14 mg), erythrosine (14 mg only) and ferric oxide yellow (7 mg, 28 mg). The black ink mainly contains shellac, black iron oxide, dehydrated alcohol, purified water and propylene glycol, with trace amount of isopropyl alcohol, butyl alcohol, strong ammonia solution and potassium hydroxide.
Obesity, a global health challenge, is influenced by biological, behavioral, socioeconomical, and environmental factors. In our technology-driven world, distracted eating is prevalent, yet neurocognitive mechanisms behind it remain poorly understood. This study targets individuals with overweight and obesity, exploring taste perception under distraction comprehensively. Participants formed two distinct groups based on their Body Mass Index (BMI), lean and overweight/obese. During the experiment participants received gustatory stimuli while playing a Tetris game of various difficulty levels. Participants rated taste intensity and pleasantness, with linear mixed models analyzing distraction effects. Results confirmed that high distraction levels reduced perception of taste intensity (p = 0.017) and taste pleasantness (p = 0.022), with variations influenced by gender and weight status. Individuals in the overweight/obese group exhibited most profound intensity changes during distraction (p = 0.01). Taste sensitivity ratings positively correlated with BMI interacting with gender (male r = 0.227, p < 0.001; female r = 0.101, p < 0.001). Overall across both groups, female participants demonstrated higher taste sensitivity compared to male participants (p < 0.001). This study highlights the impact of cognitive distraction during consumption on taste perception, particularly in relation to weight status and gender, underscoring their significant roles in this interplay.
XIST RNA is heavily studied for its role in fundamental epigenetics and X-chromosome inactivation; however, the translational potential of this singular RNA has been much less explored. This article combines elements of a review on XIST biology with our perspective on the translational prospects and challenges of XIST transgenics. We first briefly review aspects of XIST RNA basic biology that are key to its translational relevance, and then discuss recent efforts to develop translational utility of XIST for chromosome dosage disorders, particularly Down syndrome (DS). Remarkably, it was shown in vitro that expression of an XIST transgene inserted into one chromosome 21 can comprehensively silence that chromosome and "dosage compensate" Trisomy 21, the cause of DS. Here we summarize recent findings and discuss potential paths whereby ability to induce "trisomy silencing" can advance translational research for new therapeutic strategies. Despite its common nature, the underlying biology for various aspects of DS, including cell types and pathways impacted (and when), is poorly understood. Recent studies show that an inducible iPSC system to dosage-correct chromosome 21 can provide a powerful approach to unravel the cells and pathways directly impacted, and the developmental timing, information key to design pharmacotherapeutics. In addition, we discuss prospects of a more far-reaching and challenging possibility that XIST itself could be developed into a therapeutic agent, for targeted cellular "chromosome therapy". A few rare case studies of imbalanced X;autosome translocations indicate that natural XIST can rescue an otherwise lethal trisomy. The potential efficacy of XIST transgenes later in development faces substantial biological and technical challenges, although recent findings are encouraging, and technology is rapidly evolving. Hence, it is compelling to consider the transformative possibility that XIST-mediated chromosome therapy may ultimately be developed, for specific pathologies seen in DS, or other duplication disorders.
During the acute stress experimental session, subjects self-administered two generic opaque capsules. At 11:45am, subjects self-administered a capsule containing 54mg of Yohimbine Hydrochloride powder. At 12:15pm, subjects self-administered a capsule containing 10mg of Hydrocortisone.
There is only one treatment arm on this study. The combination of cirmtuzumab + docetaxel will be administered on one treatment arm. Treatment will cirmtuzumab will be administered initially as a loading dose alone on days 1, 15, and 29 of cycle 1. Following the loading, cirmtuzumab will be given on Day 1 of every 21-day cycle starting on Cycle 2 to up to Cycle 7 corresponding with concurrent docetaxel administration. Following discontinuation or completion of docetaxel, treatment with cirmtuzumab will be continued Day 1 of every 28 cycle until disease progression, toxicity or study withdrawal. Docetaxel will be administered on day 1 of every 21-day cycle starting Cycle 2 for up to 6 cycles.